Open questions include thickening and efficacy differences at 25 vs. 50.
Also, a question about the decision to market UF vs endo as a first indication. You remain skeptical about the attitude of the FDA as it relates to unmet need for UF. Knowing that safety was the major hurdle to approval for any indication with the drug and realizing that the safety hurdle for endo might not be as high for endo, can you speculate on why the company chose UF?
Market Data 
Markets 
AI
